Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.60 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.60 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | FNTA | P49354 | 1/20 | 0.44 |
| ▸ | FNTB | P49356 | 1/20 | 0.44 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 5/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28624684 | 1.00 | GPR84 (0.60) | GPR84FFAR1FFAR4KDM4ESMN1; SMN2 | |
| SCHEMBL95430 | 1.00 | GPR84 (0.60) | GPR84FFAR1FFAR4KDM4ESMN1; SMN2 | |
| 1,6-Hexanediol SCHEMBL28628065 | 1.00 | GPR84 (0.60) | GPR84FFAR1FFAR4KDM4ESMN1; SMN2 | |
| SCHEMBL5575807 | 1.00 | GPR84 (0.60) | GPR84FFAR1FFAR4KDM4ESMN1; SMN2 | |
| SCHEMBL7554526 | 1.00 | GPR84 (0.60) | GPR84FFAR1FFAR4KDM4ESMN1; SMN2 | |
| SCHEMBL2839590 | 1.00 | GPR84 (0.60) | GPR84FFAR1FFAR4KDM4ESMN1; SMN2 | |
| SCHEMBL8411317 | 1.00 | GPR84 (0.60) | GPR84FFAR1FFAR4KDM4ESMN1; SMN2 | |
| SCHEMBL1479946 | 1.00 | GPR84 (0.60) | GPR84FFAR1FFAR4KDM4ESMN1; SMN2 | |
| SCHEMBL5575804 | 1.00 | GPR84 (0.60) | GPR84FFAR1FFAR4KDM4ESMN1; SMN2 | |
| SCHEMBL6924277 | 1.00 | GPR84 (0.60) | GPR84FFAR1FFAR4KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108640861-A | \" one kettle way \" that alkynyl amide mediates prepares macrolide | 江西师范大学 | 2018-10-12 | — | — | CN | disclosed |
| US-20140050676-A1 | Method for Treating Skin with Retinoids and Retinoid Boosters | CONOPCO, INC., D/B/A UNILEVER (US) | 2014-02-20 | — | — | US | disclosed |
| US-8409550-B2 | Method for treating skin with retinoids and retinoid boosters | UNILEVER HOME & PERSONAL CARE, USA, DIVISION OF CONOPCO, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-20120258061-A1 | Method for Treating Skin with Retinoids and Retinoid Boosters | CONOPCO, INC., D/B/A UNILEVER (US) | 2012-10-11 | — | — | US | disclosed |
| US-8226933-B2 | Method for treating skin with booster compositions | UNILEVER HOME & PERSONAL CARE, USA DIVISION OF CONOPCO, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-20110206626-A1 | Method for Treating Skin with Booster Compositions | CONOPCO, INC., D/B/A UNILEVER (US) | 2011-08-25 | — | — | US | disclosed |
| US-7959913-B2 | Applying a mixture of a retinoid, antimicotic compound that enhances conversion of retinoid to retinoic acid and prevents the retinoic acid degradation (bifonazole, climbazole), fatty alcohol and/or fatty acid, and cosmetic vehicle to treat the skin for wrinkles, psoriasis, age spots or discoloration. | CONOPCO, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20080234342-A1 | Skin Conditioning Compositions Containing Compounds for Mimicking the Effect on Skin of Retinoic Acid | CONOPCO, INC., D/B/A UNILEVER (US) | 2008-09-25 | — | — | US | disclosed |
| CN-1874792-A | Compounds containing matrix metalloproteinase substrates and methods of their use | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2006-12-06 | — | — | CN | disclosed |
| EP-1219631-A1 | ANTIANDROGEN AGENTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234342-A1 | Skin Conditioning Compositions Containing Compounds for Mimicking the Effect on Skin of Retinoic Acid | RARA, RARG, RARB | GPR84 50/4885FFAR1 341/4885FFAR4 516/4885 |
| US-20120258061-A1 | Method for Treating Skin with Retinoids and Retinoid Boosters | RARA, RARG, RARB | GPR84 429/4885FFAR1 1724/4885FFAR4 1362/4885 |
| US-20110206626-A1 | Method for Treating Skin with Booster Compositions | RARB, RARA, RARG | GPR84 808/4885FFAR1 2385/4885FFAR4 2208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.